538965 — CONCORD DRUGS Income Statement
0.000.00%
- IN₹651.20m
- IN₹840.17m
- IN₹452.45m
- 37
- 25
- 90
- 50
Annual income statement for CONCORD DRUGS, fiscal year end - March 31st, INR millions except per share, conversion factor applied.
2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | 2025 March 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IAS | IAS | IAS | IAS | IAS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 514 | 590 | 521 | 449 | 452 |
| Cost of Revenue | |||||
| Gross Profit | 91.8 | 169 | 111 | 117 | 100 |
| Selling / General / Administrative Expenses | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 457 | 551 | 491 | 424 | 425 |
| Operating Profit | 56.2 | 38.3 | 29.5 | 24.9 | 27 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | 42.9 | 22.5 | 12.5 | 6.29 | 6.91 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | 32.8 | 15.9 | 9.86 | 4.72 | 3.36 |
| Net Income Before Extraordinary Items | |||||
| Net Income | 32.8 | 15.9 | 9.86 | 4.72 | 3.36 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | 32.8 | 15.9 | 9.86 | 4.72 | 3.36 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | 0.462 | 1.82 | 1.06 | 0.472 | 0.336 |